RT @TheLancetEndo: Online—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes…
RT @TheLancetEndo: Online—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes…
RT @TheLancetEndo: Online—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes…
RT @TheLancetEndo: Online—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes…
Online—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a systematic review and meta-analysis of randomised trials https://t.co/OLmuRq6zAV #T2D
【GLP-1アナログのCV保護作用:最新メタ解析/ LANCET DE】 最新のAMPLITUDE-Oを含む、2型DMを対象としたプラセボ対照RCT 98報 [60080例] 解析:GLP-1アナログで、「CV死亡・脳卒中・MI」HRは0.86 [95%CI 0.80-0.93]。HF入院も0.89 [0.82-0.98]。 https://t.co/DZnVnV6pHM
RT @Manugrillo2: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @DanielJDrucker: Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @CristobMorales: https://t.co/b1C2k1L7gf “GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MAC…
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
Great drugs to type 2 Diabetes
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @CristobMorales: https://t.co/b1C2k1L7gf “GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MAC…
RT @Manugrillo2: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic…
💪🏼 #GLP1ra #changingT2dm #proudtobepart @Hospital_Quiron @quironsalud
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @Dr_Khan: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic rev…
RT @DanielJDrucker: Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd…
RT @DanielJDrucker: Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd…
RT @Dr_Khan: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic rev…
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @AmarPut: 14% ⬇️ MACE ▪️ 12% ⬇️ all cause mortality ▪️11% ⬇️hHF ▪️21% ⬇️kidney outcomes @GoggleDocs @drkevinfernando @cardiomet_CE @DLBH…
RT @AmarPut: 14% ⬇️ MACE ▪️ 12% ⬇️ all cause mortality ▪️11% ⬇️hHF ▪️21% ⬇️kidney outcomes @GoggleDocs @drkevinfernando @cardiomet_CE @DLBH…
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @AmarPut: Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardi…
RT @DanielJDrucker: Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd…
RT @DanielJDrucker: Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd…
RT @Manugrillo2: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic…
RT @AmarPut: Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardi…
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials https://t.co/s1ATuw1eOh
RT @Dr_Khan: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic rev…
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @AmarPut: Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardi…
RT @CristobMorales: https://t.co/b1C2k1L7gf “GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MAC…
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @DanielJDrucker: Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd…
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @Dr_Khan: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic rev…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @Dr_Khan: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic rev…
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials https://t.co/N6PGVD0lpD https://t.co/ELaUXaQHx8
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @CristobMorales: https://t.co/b1C2k1L7gf “GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MAC…
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
https://t.co/b1C2k1L7gf “GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes”
RT @SDelprato: Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti…
RT @AmarPut: Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardi…
RT @AmarPut: Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardi…
RT @AmarPut: 14% ⬇️ MACE ▪️ 12% ⬇️ all cause mortality ▪️11% ⬇️hHF ▪️21% ⬇️kidney outcomes @GoggleDocs @drkevinfernando @cardiomet_CE @DLBH…
Our latest meta-analysis including recent results from AMPLITUDE-O @EASDnews @EASDelearning @DanielJDrucker @kamleshkhunti https://t.co/FMFFs63Nju
RT @CarreteroJuani: New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with t…
New more evidence of Cardiovascular, mortality, and kidney outcomes with all GLP-1 receptor agonists in patients with type 2 diabetes including heart failure. @Diabetes_SEMI @chemachir @fjcarrascos @DrPMiramontes https://t.co/94icTloMOn
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @DanielJDrucker: Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd…
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @md_arianemacedo: Important data including the recently published AMPLITUDE -O in this  systematic review and meta-analysis : Cardiova…
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials https://t.co/BfzzhEqTGN
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
Long acting GLP-1 receptor agonists are cardioprotective in people with type 2 #diabetes By the numbers https://t.co/cd9uwxP0YO
RT @AmarPut: Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardi…
RT @md_arianemacedo: Important data including the recently published AMPLITUDE -O in this  systematic review and meta-analysis : Cardiova…
RT @md_arianemacedo: Important data including the recently published AMPLITUDE -O in this  systematic review and meta-analysis : Cardiova…
Important data including the recently published AMPLITUDE -O in this  systematic review and meta-analysis : Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: https://t.co/aUCZ10p17M @RenatoDLope
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
RT @AmarPut: Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardi…
14% ⬇️ MACE ▪️ 12% ⬇️ all cause mortality ▪️11% ⬇️hHF ▪️21% ⬇️kidney outcomes @GoggleDocs @drkevinfernando @cardiomet_CE @DLBHATTMD @SABOURETCardio @BrJCardiol @DrDerekConnolly @hvanspall @pabeda1 @singhak_endo @kamleshkhunti @docwas @TheLancetEndo @PCCS_U
Less about the type/homology more about the molecule! An expected metanalysis now including AMPLITUDE-O (Efpeglenatide)😉Cardiovascular, mortality, and kidney outcomes with GLP-1 RAs in patients with T2DM : a systematic review and meta-analysis https://t.
RT @TheLancetEndo: New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a…
New—#Cardiovascular, #mortality, and #kidney outcomes with #GLP-1 receptor agonists in patients with type 2 #diabetes: a systematic review and meta-analysis of randomised trials https://t.co/OLmuRq6zAV #T2D